Charles River Laboratories Intl. Inc vs Snap Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $299.21 (market cap $14.23B), while Snap Inc trades at $6.1 (market cap $9.83B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Snap Inc for 68 Days on average.
| CRL | SNAP | |
|---|---|---|
Market Cap | $14.23B | $9.83B |
Volume | 1,176,885 | 28,532,342 |
Sector | Health | Media |
52-Week High | $310.77 | $9.09 |
52-Week Low | $149.93 | $3.93 |
Typical Hold Time | 33 Days | 68 Days |
Enterprise Value | $17.06B | $11.39B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
SNAP trades at $5.81, up 0.17% on the day, with a bullish technical signal from moving averages. The company reported revenue of $5.93B in 2025, with a net loss narrowing to -$460M, improving its profit margin to -7.77%. Recent news highlights Snap's push into enterprise AR glasses with NVIDIA and Salesforce partnerships, driving investor optimism.
The outlook remains cautious as SNAP continues to post losses despite revenue growth. Analyst consensus is a 'Hold' with a $7.78 price target, suggesting modest upside. Key risks include intense competition, regulatory pressures, and the challenge of achieving profitability. The stock's valuation appears stretched with a high EV/EBITDA of 1,149.99.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →